The use of mAbs and TKIs is not routinely employed in BC, although there are a number of ongoing EGFR-targeted clinical trials (NCT05341492, NCT05177796, NCT02593175, NCT04395989; NCT03805399) in BC and TNBC. This evidence concerns the gene EGFR and breast cancer.